1. Home
  2. LEG vs SNDX Comparison

LEG vs SNDX Comparison

Compare LEG & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Leggett & Platt Incorporated

LEG

Leggett & Platt Incorporated

HOLD

Current Price

$11.26

Market Cap

1.2B

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$20.35

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEG
SNDX
Founded
1883
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
LEG
SNDX
Price
$11.26
$20.35
Analyst Decision
Hold
Strong Buy
Analyst Count
4
12
Target Price
$10.00
$36.92
AVG Volume (30 Days)
2.2M
2.4M
Earning Date
10-27-2025
11-03-2025
Dividend Yield
1.79%
N/A
EPS Growth
N/A
N/A
EPS
1.61
N/A
Revenue
$4,172,899,999.00
$111,304,000.00
Revenue This Year
N/A
$620.14
Revenue Next Year
N/A
$115.42
P/E Ratio
$6.93
N/A
Revenue Growth
N/A
595.65
52 Week Low
$6.48
$8.58
52 Week High
$12.30
$20.59

Technical Indicators

Market Signals
Indicator
LEG
SNDX
Relative Strength Index (RSI) 68.64 69.27
Support Level $11.26 $18.36
Resistance Level $12.03 $20.20
Average True Range (ATR) 0.38 0.98
MACD 0.23 0.15
Stochastic Oscillator 77.00 92.43

Price Performance

Historical Comparison
LEG
SNDX

About LEG Leggett & Platt Incorporated

Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the majority of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: